Cargando…
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal
Industrial renewal in the bio/nanopharma sector is important for the long term strength of the Australian economy and for the health of its citizens. A variety of factors, however, may have caused inadequate attention to focus on systematically promoting domestic generic and small biotechnology manu...
Autor principal: | Faunce, Thomas A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1894805/ https://www.ncbi.nlm.nih.gov/pubmed/17543114 http://dx.doi.org/10.1186/1743-8462-4-9 |
Ejemplares similares
-
Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy
por: Faunce, Thomas, et al.
Publicado: (2005) -
'Linkage' pharmaceutical evergreening in Canada and Australia
por: Faunce, Thomas A, et al.
Publicado: (2007) -
Toward a treaty on safety and cost-effectiveness of pharmaceuticals and medical devices: enhancing an endangered global public good
por: Faunce, Thomas Alured
Publicado: (2006) -
Policy challenges from the "White" Senate inquiry into workplace-related health impacts of toxic dusts and nanoparticles
por: Faunce, Thomas A, et al.
Publicado: (2006) -
When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest
por: Ehrlich, Orna, et al.
Publicado: (2019)